Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It plans to enroll 100 participants.
Also called NCT01267448
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 100 participants
- Registry
-
NCT01267448
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01267448. Randomized; no masking; primary purpose treatment. Start 2014-09-09 (actual); primary completion 2015-07-25 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia
- Condition
- Diabetes Mellitus Type 2
- Condition
- Hyperglycemia
- Intervention (Drug)
- Glipizide XL
- Intervention (Drug)
- Saxagliptin + Metformin XR
- Intervention (Drug)
- Metformin XR
- Lead sponsor
- Cook County Health
- Collaborator
- Bristol-Myers Squibb
Record details
- Record id
cardio:ct-nct01267448- Content hash
9342ff6ed8679f29a38e6eb8d46cdfbdb1c573e93313775cb9679f482afbde8e